Avertto

Avertto is an Israeli health‑tech startup developing a subcutaneous AI‑powered carotid pulse monitor designed for real‑time stroke detection, especially large vessel occlusion (LVO).

• Continuous hemodynamic monitoring: Learns a personalized baseline from long-term carotid pulse data :contentReference[oaicite:1]{index=1}
• AI-driven detection: Deep learning + template-matching algorithms identify deviations from baseline :contentReference[oaicite:2]{index=2}
• Alert & response: On detecting elevated stroke risk, it sends GPS-enabled alerts to care providers :contentReference[oaicite:3]{index=3}

• Balloon occlusion study (n=67): 100 % sensitivity for LVO at 40 % probability threshold, with zero false positives :contentReference[oaicite:4]{index=4}
• ICU monitoring (n=10): All LVOs flagged hours to days before clinical diagnosis, no false alerts :contentReference[oaicite:5]{index=5}

• IIA funding:
  • NIS 2.5 M (Oct 2022) for development
  • NIS 5 M (Sept 2023) for multi‑center clinical trials :contentReference[oaicite:6]{index=6}
• Awards:
  • €75 K EU Women‑Tech grant (July 2022)
  • 1st prize, Hebrew University Asper competition (June 2023)
  • Forbes Aviram Awards finalist (May 2023) :contentReference[oaicite:7]{index=7}

• Dr Hilla Ben‑Pazi (CEO) – Neurologist, former tele‑neurology entrepreneur :contentReference[oaicite:8]{index=8}
• Yaniv Kirma (CTO) – 25+ years in MedTech & defense engineering :contentReference[oaicite:9]{index=9}
• Ilana Zigelman (QA/Regulatory Lead) – Ex‑FDA investigator :contentReference[oaicite:10]{index=10}
• Yair Lavi (AI/Signal Processing) – Startup AI specialist :contentReference[oaicite:11]{index=11}

• AMIT301 Class I device on track:
  • Q1 2025: US & Israel Class-I registration :contentReference[oaicite:12]{index=12}
  • Q3 2025: Planned first sales deployment :contentReference[oaicite:13]{index=13}
• Global clinical footprint: trials in Israel, Spain, USA; ICU and balloon-occlusion studies completed; astronaut (microgravity) study in collaboration with Axiom Space :contentReference[oaicite:14]{index=14}

• Avertto aims to extend continuous cerebrovascular monitoring across ICU and home settings, shifting stroke care from reactive to proactive :contentReference[oaicite:15]{index=15}
• Positioned as the first insertable AI-based stroke alert device, targeting a global market of ~120 M at-risk patients annually :contentReference[oaicite:16]{index=16}

• *Israel21c*, “Swift stroke prevention using AI and artery monitors,” Oct 15 2024 :contentReference[oaicite:17]{index=17}
• *PubMed Frontiers in Neurology*, “Pre‑hospital stroke monitoring…,” 2024 :contentReference[oaicite:18]{index=18}
• LinkedIn update by Hilla Ben‑Pazi on device milestone schedule :contentReference[oaicite:19]{index=19}